➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Harvard Business School
Moodys
Johnson and Johnson
Medtronic
Merck

Last Updated: September 27, 2021

DrugPatentWatch Database Preview

Claims for Patent: 10,028,940

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

Summary for Patent: 10,028,940
Title:Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders
Abstract: Disclosed herein are methods of treating conditions, which may be associated with elevated levels of plasma cells and/or B-cells, with a therapeutically effective amount of dexpramipexole or pharmaceutical acceptable salt thereof.
Inventor(s): Bozik; Michael E. (Pittsburgh, PA), Dworetzky; Steven (Jefferson Hills, PA)
Assignee: Knopp Biosciences LLC (Pittsburgh, PA)
Application Number:15/461,131
Patent Claims:1. A method of treating multiple myeloma in a subject comprising administering to the subject in need thereof a therapeutically effective amount of dexpramipexole or a pharmaceutically acceptable salt thereof.

2. The method of claim 1, wherein the therapeutically effective amount of dexpramipexole is from about 1 mg to about 1,000 mg per day.

3. The method of claim 1, wherein the therapeutically effective amount of dexpramipexole is from about 50 mg to about 600 mg per day.

4. The method of claim 1, wherein the therapeutically effective amount of dexpramipexole is from about 150 mg to about 300 mg per day.

5. The method of claim 1, wherein administering is selected from a group consisting of administering a fraction of the therapeutically effective amount two or more times per day, administering an amount equal to about half of the therapeutically effective amount twice per day, and administering the therapeutically effective amount every 12 hours.

6. The method of claim 1, wherein administering comprises administering about 150 mg two times per day.

7. The method of claim 1, further comprising an induction step, wherein said induction step is selected from a group consisting of administering a therapeutic agent selected from the group consisting of a glucocorticoid, a corticosteroid, a non-steroidal anti-inflammatory drug (NSAID), a tyrosine kinase inhibitor, a fusion protein, a monoclonal antibody directed against one or more pro-inflammatory cytokines, a chemotherapeutic agent, a phenolic antioxidant, an anti-proliferative drug, an anti IL-5 monoclonal antibody, an IL-5 receptor monoclonal antibody, an anti IL-13 monoclonal antibody, an anti IL-13 receptor monoclonal antibody, an anti IL-4 monoclonal antibody, an anti IL-4 receptor monoclonal antibody, an anti IgE monoclonal antibody, a TNF-.alpha. inhibitor, a fusion protein, an anti-inflammatory drug, and a combination thereof.

8. The method of claim 7, wherein the tyrosine kinase inhibitor is imatinib.

9. The method of claim 7, wherein the anti IL-5 monoclonal antibody is selected from the group consisting of mepolizumab and reslizumab.

10. The method of claim 7, wherein the IL-5 receptor monoclonal antibody is benralizumab.

11. The method of claim 7, wherein the anti IL-13 monoclonal antibody is lebrikizumab.

12. The method of claim 7, wherein the anti IL-4 receptor monoclonal antibody is dupilumab.

13. The method of claim 7, wherein the anti IgE monoclonal antibody is omalizumab.

14. The method of claim 7, wherein the TNF-.alpha. inhibitor is selected from the group consisting of infliximab, adalimumab, certolizumab pegol, and golimumab.

15. The method of claim 7, wherein the fusion protein is etanercept.

16. The method of claim 1, wherein administering comprises administering about 75 mg two times per day.

17. The method of claim 1, wherein administering comprises administering about 300 mg two times per day.

18. The method of claim 1, wherein the therapeutically effective amount of dexpramipexole is administered as an initial dosing regimen and then as a maintenance dosing regimen.

19. The method of claim 18, wherein the therapeutically effective amount of the initial dosing regimen is from about 50 mg to about 1,500 mg per day.

20. The method of claim 18, wherein the therapeutically effective amount of the initial dosing regimen is from about 150 mg to about 300 mg per day.

21. The method of claim 18, wherein the therapeutically effective amount of the initial dosing regimen is from about 300 mg to about 500 mg per day.

22. The method of claim 18, wherein the therapeutically effective amount of the initial dosing regimen is from about 300 mg to about 600 mg per day.

23. The method of claim 18, wherein the therapeutically effective amount of the maintenance dosing regimen is from about 50 mg to about 1,500 mg per day.

24. The method of claim 18, wherein the therapeutically effective amount of the maintenance dosing regimen is from about 150 mg to about 300 mg per day.

25. The method of claim 18, wherein the therapeutically effective amount of the maintenance dosing regimen is from about 300 mg to about 500 mg per day.

26. The method of claim 18, wherein the therapeutically effective amount of the maintenance dosing regimen is from about 300 mg to about 600 mg per day.

27. The method of claim 1, wherein the therapeutically effective amount is administered orally.

28. The method of claim 1, wherein the therapeutically effective amount is administered topically.

Details for Patent 10,028,940

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Centocor Inc REMICADE infliximab VIAL 103772 001 1998-08-24 ⤷  Try it Free Knopp Biosciences LLC (Pittsburgh, PA) 2033-08-13 RX Orphan search
Immunex ENBREL etanercept VIAL; SUBCUTANEOUS 103795 001 1998-11-02 ⤷  Try it Free Knopp Biosciences LLC (Pittsburgh, PA) 2033-08-13 RX Orphan search
Immunex ENBREL etanercept SYRINGE 103795 002 1998-11-02 ⤷  Try it Free Knopp Biosciences LLC (Pittsburgh, PA) 2033-08-13 RX Orphan search
Genentech XOLAIR omalizumab VIAL 103976 001 2003-06-20 ⤷  Try it Free Knopp Biosciences LLC (Pittsburgh, PA) 2033-08-13 RX search
Abbvie Inc HUMIRA adalimumab SYRINGE 125057 001 2002-12-31 ⤷  Try it Free Knopp Biosciences LLC (Pittsburgh, PA) 2033-08-13 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Boehringer Ingelheim
McKesson
Mallinckrodt
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.